Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 25, 2005. The report details a corporate action regarding the issuance of new ordinary shares rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice concerning share issuance and does not contain financial statements.
Material Changes
The primary material change reported is the application to the UK Listing Authority and the London Stock Exchange for block listings totaling 2,550,000 Ordinary shares of 25p each. These shares are to be admitted to the Official List upon issuance and will rank pari passu with existing shares.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The unusual item noted is the specific breakdown of the share issuance: 1,995,277 shares under the GlaxoSmithKline Share Option Plan and 554,723 shares under the Glaxo Group Share Option Scheme.
Investor Verification Points
- Confirm the admission of 2,550,000 new ordinary shares to the Official List.
- Verify the allocation of shares between the GlaxoSmithKline Share Option Plan and the Glaxo Group Share Option Scheme.
- Note that this filing does not include financial performance data for the period.